All News

fetus,defect,baby,malformation

Best of 2021: Potential Birth Defects with Hydroxychloroquine

d Jack Cush, MD

HCQ is one of the safest meds used in rheumatology, but new claims data suggests a small increase in the risk of malformations associated with first-trimester HCQ use. The March 2021 issue of the American Journal of Obstetrics and Gynecology studied the risk of major congenital malformations during the first trimester of pregnancy in women with rheumatic disease taking HCQ.

Read Article
burnout work overworked

Best of 2021: Rheumatologists Rank 2nd in Physician Burnout

d Jack Cush, MD

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.

The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical care (51%), Rheumatology (50%) and infectious disease (49%).

Read Article
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

d Jack Cush, MD

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults S

Read Article
knee.injx_.lat_.jpg

Best of 2021: EULAR Guidelines on Intraarticular Therapy

d Jack Cush, MD

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

Read Article
gavel judgement decide gold

Best of 2021: Rebuttals

d Kathryn H. Dao, M.D.

Since the COVID vaccine rollout, more people have been eligible to receive the vaccine. However, not everyone chooses to get one. I have heard many reasons (aka excuses) from my patients who are vaccine hesitant. 

Read Article
Voclosporin FDA Approved for Lupus Nephritis in Jan 2022 - have you used it yet? On 1/22 the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis (LN). https://t.co/vpEtzanOmp https://t.co/STbJY1N4zB

Links:

Dr. John Cush RheumNow ( View Tweet)

Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Links:

Dr. John Cush RheumNow ( View Tweet)

Drs. Len Calabrese, David Liew, Richard Conway and Sarah Mackie discuss GCA and PMR-related abstracts presented at the ACR21 annual meeting. https://t.co/3uqzWscABx https://t.co/BT0LZw7YWF

Links:

Dr. John Cush RheumNow ( View Tweet)
Third Time's the Charm - COVID Vaccination While on Rituximab https://t.co/XkXxhyYQNE https://t.co/nH8jj9xUG7

Links:

Dr. John Cush RheumNow ( View Tweet)
We're now learning about the T-cell response to Omicron after an mRNA vaccine boosters. That's why these new findings in people with multiple sclerosis on immunosuppressive therapy are very encouraging https://t.co/Gzv9sQTsuA https://t.co/SoezeVWgR3

Links:

Eric Topol EricTopol ( View Tweet)
Metanalysis of 49 articles, 16 224 pts, F/U 105 mos. Avg daily GC dose assoc w/ overall CV events, OP w/ Fx and osteonencrosis. https://t.co/l0ggQuwaaa

Links:

Dr. John Cush RheumNow ( View Tweet)

listen to my take on how out pt mgmnt for #immunocompromised pts can be optimized & how we MUST protect them fr #COVID19 @VuMedi linkhttps://bit.ly/3FfdYGB @RheumNow @NatalieEAzarMD @BolekBerqui @KDAO2011 @rhjeumn @CreakyJoints @AWIRGROUP @RNSociety @RheumAPP https://t.co/hKVIg8Aw2g
Leonard Calabrese LCalabreseDO ( View Tweet)
"When an unexpected event occurs, we look for stories, coincidences, supernatural causes & other forms of solace to explain something that frightens or surprises us. But unexpected events are usually caused by simple mechanisms" How we react is complicated https://t.co/HLQaqmzgV5

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 11 studies, 46 819 participants shows low quality evidence that knee extensor muscle weakness is assoc w/ increased the odds of knee osteoarthritis in women (OR 1.85)and men (OR 1.43); also radiographic knee OA https://t.co/Md7eODvsIy

Links:

Dr. John Cush RheumNow ( View Tweet)

AstraZeneca announced that Saphnelo (anifrolumab - Type 1 IFN receptor MAb) was recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus https://t.co/KIBWi1Nd0F

Links:

Dr. John Cush RheumNow ( View Tweet)

Indications Awaiting In the latest podcast, Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists. https://t.co/1amiQrCEWX https://t.co/YR0YSDJSg3

Links:

Dr. John Cush RheumNow ( View Tweet)
Food for Thought: "ITIS" Diet for Patients with Rheumatoid Arthritis https://t.co/C7eTPpNyXj https://t.co/G42sbDskGW

Links:

Dr. John Cush RheumNow ( View Tweet)
NSAIDS Prevent Heart Attacks in PsA https://t.co/QkJJOyK7o4 https://t.co/VDBCDHPDZ5

Links:

Dr. John Cush RheumNow ( View Tweet)
CNS Dysfunction & Blood Brain Barrier Leakage in SLE Dr. Jack Cush reviews the ACR21 Plenary Session presentation showing half of lupus patients have cognitive deficits and that these can be correlated with brain abnormalities including BBB permeability. https://t.co/HoEhqkhVlc

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced. https://t.co/nkMJUfHF6r https://t.co/cIUMVtDIKd

Links:

Dr. John Cush RheumNow ( View Tweet)
×